Haidegger M, Kneihsl M, Niederkorn K, Deutschmann H, Mangge H, Vetta C et al. Blood biomarkers of progressive atherosclerosis and restenosis after stenting of symptomatic intracranial artery stenosis. Sci Rep. 2021 Aug 2;11(1):15599.
Libby P. Inflammation in Atherosclerosis-No longer a theory. Clin Chem 2021 Jan 8;67(1):131–42.
Saigusa R, Winkels H, Ley K. T cell subsets and functions in atherosclerosis. Nat Rev Cardiol. 2020 Jul;17(7):387–401.
Packard RRS, Libby P. Inflammation in atherosclerosis: from Vascular Biology to Biomarker Discovery and Risk Prediction. Clin Chem 2008 Jan 1;54(1):24–38.
Mangge H, Hubmann H, Pilz S, Schauenstein K, Renner W, März W. Beyond cholesterol–inflammatory cytokines, the key mediators in atherosclerosis. Clin Chem Lab Med. 2004 May;42(5):467–74.
Mani P, Puri R, Schwartz GG, Nissen SE, Shao M, Kastelein JJP et al. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome. JAMA Cardiol. 2019 Apr 1;4(4):314.
Carrero JJ, Andersson Franko M, Obergfell A, Gabrielsen A, Jernberg T. hsCRP level and the risk of Death or Recurrent Cardiovascular events in patients with myocardial infarction: a Healthcare-Based study. J Am Heart Assoc. 2019 Jun 4;8(11).
Shahzad S, Mateen S, Hasan A, Moin S. GRACE score of myocardial infarction patients correlates with oxidative stress index, hsCRP and inflammation. Immunobiology. 2019 May;224(3):433–9.
Groot HE, Al Ali L, van der Horst ICC, Schurer RAJ, van der Werf HW, Lipsic E, et al. Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction. Clin Res Cardiol. 2019 Jun;108(6):612–21.
Tiller C, Reindl M, Holzknecht M, Lechner I, Schwaiger J, Brenner C, et al. Association of plasma interleukin-6 with infarct size, reperfusion injury, and adverse remodelling after ST-elevation myocardial infarction. Eur Hear journal Acute Cardiovasc care. 2022 Feb;8(2):113–23.
Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018 Jan;391(10118):319–28.
Abbate A, Trankle CR, Buckley LF, Lipinski MJ, Appleton D, Kadariya D et al. Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST‐Segment–Elevation Myocardial Infarction. J Am Heart Assoc. 2020 Mar 3;9(5).
Wang J, Wang M, Lu X, Zhang Y, Zeng S, Pan X, et al. IL-6 inhibitors effectively reverse post-infarction cardiac injury and ischemic myocardial remodeling via the TGF-β1/Smad3 signaling pathway. Exp Ther Med. 2022 Sep;24(3):576.
Dogan I, Karaman K, Sonmez B, Celik S, Turker O. Relationship between serum neutrophil count and infarct size in patients with acute myocardial infarction. Nucl Med Commun. 2009 Oct;30(10):797–801.
Chia S, Nagurney JT, Brown DFM, Raffel OC, Bamberg F, Senatore F et al. Association of leukocyte and neutrophil counts with infarct size, left ventricular function and outcomes after percutaneous coronary intervention for ST-elevation myocardial infarction. Am J Cardiol. 2009 Feb 1;103(3):333–7.
Dharma S, Hapsari R, Siswanto BB, van der Laarse A, Jukema JW. Blood leukocyte count on Admission Predicts Cardiovascular events in patients with Acute Non-ST elevation myocardial infarction. Int J Angiol. 2015 Jun;24(2):127–32.
Chen C, Cong BL, Wang M, Abdullah M, Wang XL, Zhang YH, et al. Neutrophil to lymphocyte ratio as a predictor of myocardial damage and cardiac dysfunction in acute coronary syndrome patients. Integr Med Res. 2018 Jun;7(2):192–9.
Ji Z, Liu G, Guo J, Zhang R, Su Y, Carvalho A, et al. The neutrophil-to-lymphocyte ratio is an important Indicator Predicting In-Hospital death in AMI Patients. Front Cardiovasc Med. 2021;8:706852.
Wang H, Li L, Ma Y. Platelet-to-lymphocyte ratio a potential prognosticator in acute myocardial infarction: a prospective longitudinal study. Clin Cardiol. 2023 Apr 14.
Maimaiti A, Li Y, Wang Y-T, Yang X, Li X-M, Yang Y-N et al. Association of platelet-to-lymphocyte count ratio with myocardial reperfusion and major adverse events in patients with acute myocardial infarction: a two-centre retrospective cohort study. BMJ Open. 2019 Sep 18;9(9):e025628.
Dong G, Huang A, Liu L. Platelet-to-lymphocyte ratio and prognosis in STEMI: a meta-analysis. Eur J Clin Invest. 2021 Mar;51(3):e13386.
Karadeniz F, Karadeniz Y, Altuntaş E. Systemic immune-inflammation index, and neutrophilto-lymphocyte and platelet-to-lymphocyte ratios can predict clinical outcomes in patients with acute coronary syndrome. Cardiovasc J Afr. 2023 May;5:34:1–7.
Yildiz A, Yuksel M, Oylumlu M, Polat N, Akyuz A, Acet H, et al. The utility of the platelet-lymphocyte ratio for Predicting No Reflow in Patients with ST-Segment Elevation myocardial infarction. Clin Appl Thromb Hemost. 2015 Apr;21(3):223–8.
Vakili H, Shirazi M, Charkhkar M, Khaheshi I, Memaryan M, Naderian M. Correlation of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with thrombolysis in myocardial infarction frame count in ST-segment elevation myocardial infarction. Eur J Clin Invest. 2017 Apr;47(4):322–7.
Paolisso P, Bergamaschi L, Santulli G, Gallinoro E, Cesaro A, Gragnano F, et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol. 2022;21(1):77.
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with Empagliflozin in Heart failure. N Engl J Med. 2020;383(15):1413–24.
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet (London, England). 2020 Sep 19;396(10254):819–29.
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart failure with a preserved ejection fraction. N Engl J Med. 2021 Aug;27(36):3599–726.
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF et al. Dapagliflozin in Heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022 Aug 27.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18).
von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022 Nov;1(41):4421–32.
Tripolt NJ, Kolesnik E, Pferschy PN, Verheyen N, Ablasser K, Sailer S, et al. Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-the EMMY trial. Am Heart J. 2020;221:39–47.
Lawler PR, Bhatt DL, Godoy LC, Lüscher TF, Bonow RO, Verma S, et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021 Jan;1(1):113–31.
Grufman H, Yndigegn T, Gonçalves I, Nilsson J, Schiopu A. Elevated IL-27 in patients with acute coronary syndrome is associated with adverse ventricular remodeling and increased risk of recurrent myocardial infarction and cardiovascular death. Cytokine. 2019 Oct;122:154208.
Ridker PM. From C-Reactive protein to Interleukin-6 to Interleukin-1: moving Upstream to identify novel targets for atheroprotection. Circ Res 2016 Jan 8;118(1):145–56.
La Grotta R, de Candia P, Olivieri F, Matacchione G, Giuliani A, Rippo MR et al. Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin. Cell Mol Life Sci. 2022 May 3;79(5):273.
Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP. Diabetes mellitus and inflammation. Curr Diab Rep. 2013 Jun;13(3):435–44.
Karpiński L, Płaksej R, Kosmala W, Witkowska M. Serum levels of interleukin-6, interleukin-10 and C-reactive protein in relation to left ventricular function in patients with myocardial infarction treated with primary angioplasty. Kardiol Pol. 2008 Dec;66(12):1279–85.
Oprescu N, Micheu MM, Scafa-Udriste A, Popa-Fotea N-M, Dorobantu M. Inflammatory markers in acute myocardial infarction and the correlation with the severity of coronary heart disease. Ann Med. 2021 Dec;53(1):1041–7.
Swiatkiewicz I, Taub PR. The usefulness of C-reactive protein for the prediction of post-infarct left ventricular systolic dysfunction and heart failure. Kardiol Pol. 2018;76(5):821–9.
van Diepen S, Newby LK, Lopes RD, Stebbins A, Hasselblad V, James S, et al. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. Int J Cardiol. 2013 Oct;3(3):2127–33.
Tøllefsen IM, Shetelig C, Seljeflot I, Eritsland J, Hoffmann P, Andersen G. High levels of interleukin-6 are associated with final infarct size and adverse clinical events in patients with STEMI. Open Hear. 2021 Dec;8(2).
Koyani CN, Plastira I, Sourij H, Hallström S, Schmidt A, Rainer PP, et al. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. Pharmacol Res. 2020;158:104870.
Agarwal R, Aurora RG, Siswanto BB, Muliawan HS. The prognostic value of neutrophil-to-lymphocyte ratio across all stages of coronary artery disease. Coron Artery Dis. 2022 Mar 1;33(2):137–43.
Tahto E, Jadric R, Pojskic L, Kicic E. Neutrophil-to-lymphocyte ratio and its relation with markers of inflammation and myocardial necrosis in patients with Acute Coronary Syndrome. Med Arch (Sarajevo, Bosnia Herzegovina). 2017 Oct;71(5):312–5.
Zhang S, Diao J, Qi C, Jin J, Li L, Gao X et al. Predictive value of neutrophil to lymphocyte ratio in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention: a meta-analysis. BMC Cardiovasc Disord. 2018 May 2;18(1):75.
Yoon GS, Choi SH, Woo SI, Baek YS, Park SD, Shin SH, et al. Neutrophil-to-lymphocyte ratio at Emergency Room predicts mechanical complications of ST-segment elevation myocardial infarction. J Korean Med Sci. 2021 May;17(19):e131.
Erkol A, Oduncu V, Turan B, Kiliçgedik A, Karabay CY, Akgün T, et al. Neutrophil to lymphocyte ratio in acute ST-segment elevation myocardial infarction. Am J Med Sci. 2014 Jul;348(1):37–42.
Dolu AK, Karayiğit O, Ozkan C, Çelik MC, Kalçık M. Relationship between intracoronary thrombus burden and systemic immune-inflammation index in patients with ST-segment elevation myocardial infarction. Acta Cardiol. 2023 Feb;78(1):72–9.
Pinheiro Machado G, Araujo GN, Carpes CK, Lech MC, Mariani S, Valle FH, et al. Elevated neutrophil-to-lymphocyte ratio can predict procedural adverse events in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis. 2019 Jan;30(1):20–5.
Liang Y, Chen H, Wang P. Correlation of Leukocyte and Coronary Lesion Severity of Acute Myocardial Infarction. Angiology. 2018 Aug;69(7):591–9.
Wang Z, Ren L, Lei L, Ye H, Peng J. The relationship between neutrophil counts on admission and angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Acta Cardiol. 2016 Apr;71(2):241–6.
Li L, Ma Y, Geng X-B, Tan Z, Wang J-H, Cui C, et al. Platelet-to-lymphocyte ratio relates to poor prognosis in elderly patients with acute myocardial infarction. Aging Clin Exp Res. 2021 Mar;33(3):619–24.
Pujani M, Chauhan V, Singh K, Rastogi S, Agarwal C, Gera K. The effect and correlation of smoking with platelet indices, neutrophil lymphocyte ratio and platelet lymphocyte ratio. Hematol Transfus cell Ther. 2021;43(4):424–9.
Anzai T. Inflammatory mechanisms of Cardiovascular Remodeling. Circ J 2018 Feb 23;82(3):629–35.
Kologrivova I, Shtatolkina M, Suslova T, Ryabov V. Cells of the Immune System in Cardiac Remodeling: main players in resolution of inflammation and repair after myocardial infarction. Front Immunol. 2021;12:664457.
Huang M, Yang D, Xiang M, Wang J. Role of interleukin-6 in regulation of immune responses to remodeling after myocardial infarction. Heart Fail Rev. 2015 Jan;20(1):25–38.
Fonseca FA, Izar MC. Role of inflammation in Cardiac Remodeling after Acute myocardial infarction. Front Physiol. 2022;13:927163.